SCHEMBL19409291

SCHEMBL19409291

CN(CCN(C)C(=O)OC(C)(C)C)Cc1cn(C2CCCCO2)nc1-c1ccc(O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 6/20 0.40
SLC6A4 P31645 6/20 0.40
HTR2A P28223 1/20 0.35
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
PKM P14618 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ABL1 P00519 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
GAA P10253 1/20 0.31
CD274 Q9NZQ7 1/20 0.31
AAK1 Q2M2I8 1/20 0.30
CYP4F2 P78329 1/20 0.30
CYP4A11 Q02928 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16068284 0.93 HTR2C (0.38) HTR2CSLC6A4HTR2AMEN1ALDH1A1
SCHEMBL16068182 0.91 HTR2C (0.37) HTR2CSLC6A4HTR2AMEN1ALDH1A1
SCHEMBL16201299 0.90 HTR2C (0.36) HTR2CSLC6A4HTR2AMEN1ALDH1A1
SCHEMBL16058330 0.90 HTR2C (0.36) HTR2CSLC6A4HTR2AMEN1ALDH1A1
SCHEMBL16103308 0.89 HTR2C (0.41) HTR2CSLC6A4HTR2AMEN1ALDH1A1
SCHEMBL16103309 0.89 HTR2C (0.41) HTR2CSLC6A4HTR2AMEN1ALDH1A1
SCHEMBL17610254 0.89 HTR2C (0.36) HTR2CSLC6A4HTR2AMEN1ALDH1A1
SCHEMBL17621973 0.89 HTR2C (0.36) HTR2CSLC6A4HTR2AMEN1ALDH1A1
SCHEMBL20393077 0.89 HTR2C (0.36) HTR2CSLC6A4HTR2AMEN1ALDH1A1
SCHEMBL16194361 0.88 HTR2C (0.37) HTR2CSLC6A4HTR2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190077795-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2019-03-14 US disclosed
US-20170283400-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077795-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 HTR2C 4449/4885SLC6A4 2495/4885HTR2A 3980/4885
US-20170283400-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 HTR2C 4449/4885SLC6A4 2495/4885HTR2A 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.